|
1
|
DeBerardinis RJ and Cheng T: Q's next: The
diverse functions of glutamine in metabolism, cell biology and
cancer. Oncogene. 29:313–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barger JF and Plas DR: Balancing
biosynthesis and bioenergetics: Metabolic programs in oncogenesis.
Endocr Relat Cancer. 17:R287–R304. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cantor JR and Sabatini DM: Cancer cell
metabolism: One hallmark, many faces. Cancer Discov. 2:881–898.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu W, Le A, Hancock C, Lane AN, Dang CV,
Fan TW-M and Phang JM: Reprogramming of proline and glutamine
metabolism contributes to the proliferative and metabolic responses
regulated by oncogenic transcription factor c-MYC. Proc Natl Acad
Sci USA. 109:8983–8988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen JQ and Russo J: Dysregulation of
glucose transport, glycolysis, TCA cycle and glutaminolysis by
oncogenes and tumor suppressors in cancer cells. Biochim Biophys
Acta. 1826:370–384. 2012.PubMed/NCBI
|
|
7
|
Kuhn KS, Muscaritoli M, Wischmeyer P and
Stehle P: Glutamine as indispensable nutrient in oncology:
Experimental and clinical evidence. Eur J Nutr. 49:197–210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Polet F and Feron O: Endothelial cell
metabolism and tumour angiogenesis: Glucose and glutamine as
essential fuels and lactate as the driving force. J Intern Med.
273:156–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahluwalia GS, Grem JL, Hao Z and Cooney
DA: Metabolism and action of amino acid analog anti-cancer agents.
Pharmacol Ther. 46:243–271. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rubio IT, Cao Y, Hutchins LF, Westbrook KC
and Klimberg VS: Effect of glutamine on methotrexate efficacy and
toxicity. Ann Surg. 227:772–778; discussion 778–780. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cluntun AA, Lukey MJ, Cerione RA and
Locasale JW: Glutamine Metabolism in Cancer: Understanding the
Heterogeneity. Trends Cancer. 3:169–180. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi YK and Park KG: Targeting Glutamine
Metabolism for Cancer Treatment. Biomol Ther (Seoul). 26:19–28.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anderson PM and Lalla RV: Glutamine for
Amelioration of Radiation and Chemotherapy Associated Mucositis
during Cancer Therapy. Nutrients. 12:16752020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Savarese DM, Savy G, Vahdat L, Wischmeyer
PE and Corey B: Prevention of chemotherapy and radiation toxicity
with glutamine. Cancer Treat Rev. 29:501–513. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Papanikolopoulou A, Syrigos KN and
Drakoulis N: The role of glutamine supplementation in thoracic and
upper aerodigestive malignancies. Nutr Cancer. 67:231–237. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subramaniam AV, Salem Yehya AH and Oon CE:
Molecular Basis of Cancer Pain Management: An Updated Review.
Medicina (Kaunas). 55:5842019. View Article : Google Scholar
|
|
18
|
van den Berg H: Asparaginase revisited.
Leuk Lymphoma. 52:168–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jaffe N, Traggis D, Das L, Moloney WC,
Hann HW, Kim BS and Nair R: L-asparaginase in the treatment of
neoplastic diseases in children. Cancer Res. 31:942–949.
1971.PubMed/NCBI
|
|
20
|
Jia ZY, Shen TY, Jiang W and Qin HL:
Identification of molecular mechanisms of glutamine in pancreatic
cancer. Oncol Lett. 14:6395–6402. 2017.PubMed/NCBI
|
|
21
|
Stanciu AE, Zamfir-Chiru-Anton A, Stanciu
MM, Stoian AP, Jinga V, Nitipir C, Bucur A, Pituru TS, Arsene AL,
Dragoi CM, et al: Clinical significance of serum melatonin in
predicting the severity of oral squamous cell carcinoma. Oncol
Lett. 19:1537–1543. 2020.PubMed/NCBI
|
|
22
|
Olaru OT, Venables L, VAN DE Venter M,
Nitulescu GM, Margina D, Spandidos DA and Tsatsakis AM: Anticancer
potential of selected Fallopia Adans species. Oncol Lett.
10:1323–1332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pavlova NN, Hui S, Ghergurovich JM, Fan J,
Intlekofer AM, White RM, Rabinowitz JD, Thompson CB and Zhang J: As
Extracellular Glutamine Levels Decline, Asparagine Becomes an
Essential Amino Acid. Cell Metab. 27:428–438.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bobrovnikova-Marjon EV, Marjon PL, Barbash
O, Vander Jagt DL and Abcouwer SF: Expression of angiogenic factors
vascular endothelial growth factor and interleukin-8/CXCL8 is
highly responsive to ambient glutamine availability: Role of
nuclear factor-kappaB and activating protein-1. Cancer Res.
64:4858–4869. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishak Gabra MB, Yang Y, Li H, Senapati P,
Hanse EA, Lowman XH, Tran TQ, Zhang L, Doan LT, Xu X, et al:
Dietary glutamine supplementation suppresses
epigenetically-activated oncogenic pathways to inhibit melanoma
tumour growth. Nat Commun. 11:33262020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J, Pavlova NN and Thompson CB:
Cancer cell metabolism: The essential role of the nonessential
amino acid, glutamine. EMBO J. 36:1302–1315. 2017. View Article : Google Scholar
|
|
27
|
García-de-Lorenzo A, Zarazaga A,
García-Luna PP, Gonzalez-Huix F, López-Martínez J, Miján A, Quecedo
L, Casimiro C, Usán L and del Llano J: Clinical evidence for
enteral nutritional support with glutamine: A systematic review.
Nutrition. 19:805–811. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marur S and Forastiere AA: Head and Neck
Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and
Treatment. Mayo Clin Proc. 91:386–396. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bayman NA, Blackhall F, Jain P, Lee L,
Thatcher N and Faivre-Finn C: Management of unresectable stage III
non-small-cell lung cancer with combined-modality therapy: A review
of the current literature and recommendations for treatment. Clin
Lung Cancer. 9:92–101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang EY, Leung SW, Wang CJ, Chen HC, Sun
LM, Fang FM, Yeh SA, Hsu HC and Hsiung CY: Oral glutamine to
alleviate radiation-induced oral mucositis: A pilot randomized
trial. Int J Radiat Oncol Biol Phys. 46:535–539. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sarumathy S, Ismail AM and Palasimany A:
Efficacy and safety of oral glutamine in radiation induced oral
mucositis in patients with Head and Neck cancer. Asian J Pharm Clin
Res. 5:138–140. 2012.
|
|
32
|
Zygogianni A, Kyrgias G, Kouvaris J,
Pistevou-Gombaki K, Capezzali G, Zefkili S, Kokkakis J,
Georgakopoulos J, Kelekis K and Kouloulias V: Impact of acute
radiation induced toxicity of glutamine administration in several
hypofractionated irradiation schedules for head and neck carcinoma.
Head Neck Oncol. 4:86–92. 2012.
|
|
33
|
Chattopadhyay S, Saha A, Azam M, Mukherjee
A and Sur PK: Role of oral glutamine in alleviation and prevention
of radiation-induced oral mucositis: A prospective randomized
study. South Asian J Cancer. 3:8–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsujimoto T, Yamamoto Y, Wasa M, Takenaka
Y, Nakahara S, Takagi T, Tsugane M, Hayashi N, Maeda K, Inohara H,
et al: L-glutamine decreases the severity of mucositis induced by
chemoradiotherapy in patients with locally advanced head and neck
cancer: A double-blind, randomized, placebo-controlled trial. Oncol
Rep. 33:33–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pattanayak L, Panda N, Dash MK, Mohanty S
and Samantaray S: Management of Chemoradiation-Induced Mucositis in
Head and Neck Cancers With Oral Glutamine. J Glob Oncol. 2:200–206.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lopez-Vaquero D, Gutierrez-Bayard L,
Rodriguez-Ruiz JA, Saldaña-Valderas M and Infante-Cossio P:
Double-blind randomized study of oral glutamine on the management
of radio/chemotherapy-induced mucositis and dermatitis in head and
neck cancer. Mol Clin Oncol. 6:931–936. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pachón Ibáñez J, Pereira Cunill JL, Osorio
Gómez GF, Irles Rocamora JA, Serrano Aguayo P, Quintana Ángel B,
Fuentes Pradera J, Chaves Conde M, Ortiz Gordillo MJ and García
Luna PP: Prevention of oral mucositis secondary to antineoplastic
treatments in head and neck cancer by supplementation with oral
glutamine. Nutr Hosp. 35:428–433. 2018.PubMed/NCBI
|
|
38
|
Huang CJ, Huang MY, Fang PT, Chen F, Wang
YT, Chen CH, Yuan SS, Huang CM, Luo KH, Chuang HY, et al:
Randomized double-blind, placebo-controlled trial evaluating oral
glutamine on radiation-induced oral mucositis and dermatitis in
head and neck cancer patients. Am J Clin Nutr. 109:606–614. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pathak S, Soni TP, Sharma LM, Patni N and
Gupta AK: A Randomized Controlled Trial to Evaluate the Role and
Efficacy of Oral Glutamine in the Treatment of
Chemo-radiotherapy-induced Oral Mucositis and Dysphagia in Patients
with Oropharynx and Larynx Carcinoma. Cureus.
11:e48552019.PubMed/NCBI
|
|
40
|
Algara M, Rodríguez N, Viñals P, Lacruz M,
Foro P, Reig A, Quera J, Lozano J, Fernández-Velilla E, Membrive I,
et al: Prevention of radiochemotherapy-induced esophagitis with
glutamine: Results of a pilot study. Int J Radiat Oncol Biol Phys.
69:342–349. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Topkan E, Yavuz MN, Onal C and Yavuz AA:
Prevention of acute radiation-induced esophagitis with glutamine in
non-small cell lung cancer patients treated with radiotherapy:
Evaluation of clinical and dosimetric parameters. Lung Cancer.
63:393–399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Topkan E, Parlak C, Topuk S and Pehlivan
B: Influence of oral glutamine supplementation on survival outcomes
of patients treated with concurrent chemoradiotherapy for locally
advanced non-small cell lung cancer. BMC Cancer. 12:502–512. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gul K, Muge A, Taner A and Sehri E: Oral
glutamine supplementation reduces radiotherapy- induced esophagitis
in lung cancer patients. Asian Pac J Cancer Prev. 16:53–58. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chang SC, Lai YC, Hung JC and Chang CY:
Oral glutamine supplements reduce concurrent
chemoradiotherapy-induced esophagitis in patients with advanced
non-small cell lung cancer. Medicine (Baltimore). 98:e144632019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sayles C, Hickerson SC, Bhat RR, Hall J,
Garey KW and Trivedi MV: Oral Glutamine in Preventing
Treatment-Related Mucositis in Adult Patients With Cancer: A
Systematic Review. Nutr Clin Pract. 31:171–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Leung HW and Chan AL: Glutamine in
Alleviation of Radiation-Induced Severe Oral Mucositis: A
Meta-Analysis. Nutr Cancer. 68:734–742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang G, Huang W, Zhang L and Wei Z: Role
of Glutamine in the Management of Oral Mucositis in Patients with
Cancer: A Meta-Analysis of Randomized Controlled Trials. Nutr
Cancer. 19:1–14. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peng TR, Lin HH, Yang LJ and Wu TW:
Correction to: Effectiveness of glutamine in the management of oral
mucositis in cancer patients: a meta-analysis of randomized
controlled trials. Support Care Cancer. 29:48932021. View Article : Google Scholar : PubMed/NCBI
|
